Regeneron Pharmaceuticals (REGN) Operating Leases (2022 - 2025)

Regeneron Pharmaceuticals' Operating Leases history runs 4 years deep, the most recent figure standing at $986.8 million for Q4 2025.

• In Q4 2025, Operating Leases rose 3.39% year-over-year to $986.8 million; the TTM figure through Dec 2025 stood at $986.8 million (up 3.39% YoY), while the FY2025 annual figure was $986.8 million, up 3.39% from the prior year.
• Operating Leases for Q4 2025 stood at $986.8 million, up from $954.4 million in the prior quarter.
• The five-year high for Operating Leases was $986.8 million in Q4 2025, with the low at $788.2 million in Q4 2022.
• The 4-year median for Operating Leases is $881.0 million (2023), against an average of $884.3 million.
• The sharpest annual moves came in 2023 and 2024: Operating Leases climbed 2.47% in 2023, then rose 18.16% in 2024.
• Regeneron Pharmaceuticals' Operating Leases stood at $788.2 million in 2022, then grew by 2.47% to $807.7 million in 2023, then grew by 18.16% to $954.4 million in 2024, then advanced by 3.39% to $986.8 million in 2025.
• Business Quant data shows REGN's Operating Leases at $986.8 million in Q4 2025, $954.4 million in Q4 2024, and $807.7 million in Q4 2023.